Edwards Lifesciences Stock Forecast, Price & News

Edwards Lifesciences' stock was trading at $65.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EW shares have increased by 33.6% and is now trading at $87.87.
View which stocks have been most impacted by COVID-19.

21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 2 sell ratings, 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Edwards Lifesciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares.
View analyst ratings for Edwards Lifesciences or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Edwards Lifesciences a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Edwards Lifesciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Edwards Lifesciences is scheduled to release its next quarterly earnings announcement on Wednesday, January 27th 2021.
View our earnings forecast for Edwards Lifesciences.

Edwards Lifesciences will be holding an earnings conference call on Wednesday, January 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Edwards Lifesciences Co. (NYSE:EW) announced its earnings results on Wednesday, October, 21st. The medical research company reported $0.51 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.45 by $0.06. The medical research company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.08 billion. Edwards Lifesciences had a net margin of 18.18% and a return on equity of 29.00%.
View Edwards Lifesciences' earnings history.

Edwards Lifesciences shares split before market open on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly minted shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 300 shares after the split.

Edwards Lifesciences updated its FY 2021 IntraDay earnings guidance on Thursday, December, 10th. The company provided earnings per share (EPS) guidance of 2.00-2.20 for the period, compared to the Thomson Reuters consensus estimate of $2.22. The company issued revenue guidance of $4.9-5.3 billion, compared to the consensus revenue estimate of $5.1 billion.

21 brokers have issued 12 month price targets for Edwards Lifesciences' shares. Their forecasts range from $51.67 to $111.00. On average, they anticipate Edwards Lifesciences' stock price to reach $90.87 in the next twelve months. This suggests a possible upside of 3.4% from the stock's current price.
View analysts' price targets for Edwards Lifesciences or view Wall Street analyst' top-rated stocks.

Some companies that are related to Edwards Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Hologic (HOLX), Insulet (PODD), Teleflex (TFX), Varian Medical Systems (VAR) and STERIS (STE).
View all of EW's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), The Home Depot (HD), salesforce.com (CRM), The Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS).

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.16%), Huntington National Bank (0.12%), Ardevora Asset Management LLP (0.10%), Gateway Investment Advisers LLC (0.04%), Scout Investments Inc. (0.04%) and Endurance Wealth Management Inc. (0.04%). Company insiders that own Edwards Lifesciences stock include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link.
View institutional ownership trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including Huntington National Bank, Scout Investments Inc., State of Alaska Department of Revenue, Bright Rock Capital Management LLC, Abner Herrman & Brock LLC, Crossmark Global Holdings Inc., First American Bank, and TrimTabs Asset Management LLC. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, and Scott B Ullem.
View insider buying and selling activity for Edwards Lifesciences or view top insider-selling stocks.

EW stock was bought by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Grant GrossMendelsohn LLC, IFM Investors Pty Ltd, Louisiana State Employees Retirement System, Cullinan Associates Inc., Raymond James Trust N.A., and Rowland Carmichael Advisors Inc. ADV.
View insider buying and selling activity for Edwards Lifesciences or or view top insider-buying stocks.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EW stock can currently be purchased for approximately $87.87.

Edwards Lifesciences has a market capitalization of $54.76 billion and generates $4.35 billion in revenue each year. The medical research company earns $1.05 billion in net income (profit) each year or $1.86 on an earnings per share basis. Edwards Lifesciences employs 13,900 workers across the globe.

The official website for Edwards Lifesciences is www.edwards.com.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]